Group 1 - The core viewpoint of the news is that Kosen Technology has shown significant stock performance, with an 80.13% increase in stock price year-to-date and a recent 2.03% rise in intraday trading [1] - As of December 19, Kosen Technology's stock price is reported at 14.05 yuan per share, with a total market capitalization of 7.796 billion yuan [1] - The company has experienced a net inflow of main funds amounting to 11.14 million yuan, with significant buying and selling activity from large orders [1] Group 2 - Kosen Technology, established on December 1, 2010, specializes in precision manufacturing processes and serves notable clients such as Apple, Amazon, and Google [2] - The company's revenue composition includes 76.75% from consumer electronics, 10.58% from new energy-storage business, and 8.10% from medical surgical instruments [2] - As of September 30, the number of shareholders increased by 27.57% to 94,300, while the average circulating shares per person decreased by 21.61% [2] Group 3 - Kosen Technology has distributed a total of 283 million yuan in dividends since its A-share listing, with 71.68 million yuan distributed over the past three years [3]

Group 1 - The core viewpoint of the news is that Kosen Technology's stock has experienced significant fluctuations, with a year-to-date increase of 77.18% and a recent decline in trading performance [1] - As of December 18, Kosen Technology's stock price was 13.82 yuan per share, with a total market capitalization of 7.668 billion yuan [1] - The company has seen a net outflow of main funds amounting to 49.86 million yuan, with large orders showing a buy of 91.67 million yuan and a sell of 128 million yuan [1] Group 2 - Kosen Technology, established on December 1, 2010, specializes in precision manufacturing processes and serves major clients like Apple, Amazon, and Google [2] - The company's revenue composition includes 76.75% from consumer electronics, 10.58% from new energy-storage business, and 8.10% from medical surgical instruments [2] - As of September 30, the number of shareholders increased by 27.57% to 94,300, while the average circulating shares per person decreased by 21.61% [2] Group 3 - Kosen Technology has distributed a total of 283 million yuan in dividends since its A-share listing, with 71.68 million yuan distributed over the past three years [3]

Core Viewpoint - Kosen Technology is facing scrutiny over its decision to sell its profitable subsidiary, Kosen Medical, amid ongoing losses, raising questions about the company's future strategic direction and operational viability [1][2]. Group 1: Company Strategy and Financial Performance - Kosen Technology plans to sell Kosen Medical for 915 million RMB, achieving a significant valuation increase of 206.45%, which is intended to enhance its financial performance [1]. - The company has reported consecutive losses for two years, with projected net losses of 281 million RMB in 2023 and 477 million RMB in 2024, indicating ongoing financial challenges [2]. - The sale is part of a broader strategy to optimize business operations and restructure finances, aiming to return to profitability while focusing on high-growth areas such as thermal management modules and robotic components [2]. Group 2: Investor Concerns and Transparency - Investors express concerns regarding the potential impact of asset sales on their interests, questioning the rationale behind selling a profitable asset during a period of financial distress [2]. - Kosen Technology is urged to improve transparency in its disclosures, providing detailed information about the transaction, including valuation methods and expected future benefits, to reassure investors [2]. - The company is also advised to strengthen its strategic planning and clarify the pathways and expected returns of new business initiatives to build investor confidence in its future direction [2][3].

Core Viewpoint - Kosen Technology's sale of its core medical subsidiary has triggered regulatory inquiries due to concerns over the necessity and rationale of divesting quality assets rather than inefficient ones, potentially harming investor interests [1] Group 1: Financial Performance - Kosen Medical achieved net profits of 41.12 million yuan and 47.24 million yuan in the first three quarters of 2024 and 2025, respectively, indicating continuous growth, while the parent company continues to incur losses [1] Group 2: Reasons for Asset Sale - The primary reason for the sale is "pressure to expand overseas," as geopolitical factors have led core clients to demand overseas production capabilities, which Kosen cannot meet due to stringent regulations and high investment costs for new factories [1] - The second reason is "valuation realization," with Kosen Medical's earnings-based valuation at a price-to-earnings ratio of 11.91, which is within a reasonable market range. The sale is expected to generate 915 million yuan in cash, covering current losses and improving financial statements, which is crucial for maintaining client trust and securing new orders [1] Group 3: Challenges in Disposing Inefficient Assets - In contrast, disposing of inefficient assets is described as "easier said than done." The company has initiated the disposal of idle factories and equipment valued at approximately 440 million yuan since 2024, but market valuation is limited due to technological risks and a downturn in the industrial real estate market, making it difficult to reach price agreements [2]

证券日报网讯12月16日晚间，科森科技（603626）发布公告称，公司定于2025年12月24日召开2025年第 三次临时股东大会。 ...

金证(上海)资产评估有限公司 关于上海证券交易所 《关于昆山科森科技股份有限公司出售全资子公司股权的 监管工作函》 评估相关问题回复 金证(上海)资产评估有限公司 二〇二五年十二月 资产评 UATION&CONSULTING 上海证券交易所: 根据上海证券交易所 2025年 12月 8日出具的《关于昆山科森科技股 份有限公司出售全资子公司股权的监管工作函》(上证公函(2025)4004 号) (以下简称"工作函")的要求,金证(上海)资产评估有限公司(以下 简称"金证评估""评估机构")本着勤勉尽责、诚实守信的原则,对工作 函所提出的问题进行了认真研究和落实,并按照工作函的要求对所涉及的 问题进行了回复,现提交贵所,请予审核。 本工作函回复部分表格中单项数据加总数与表格合计数可能存在微小 差异,均因计算过程中的四舍五入所形成。本工作函回复的字体代表以下 含义: | 类别 | 字体 | | --- | --- | | 黑体(加粗) | 工作函所列问题 | | 宋体 | 对工作函所列问题的回复 | 上海市徐汇区龙兰路 277 号东航滨江中心 T3 栋 7F | 021-63081130 | https://www ...

地址：上海市浦东新区银城中路 501 号上海中心大厦 11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 上海市锦天城律师事务所 关于上海证券交易所 《关于昆山科森科技股份有限公司 出售全资子公司股权的监管工作函》所涉法律事项的 法律意见书 关于上海证券交易所《关于昆山科森科技股份有限公司 出售全资子公司股权的监管工作函》所涉法律事项的 法律意见书 昆山科森科技股份有限公司： 上海市锦天城律师事务所（以下简称"本所"）接受昆山科森科技股份有限 公司（以下简称"贵司"或"公司"或"科森科技"）委托，作为昆山科森科技 股份有限公司常年法律顾问，就上海证券交易所于 2025 年 12 月 8 日出具的《关 于昆山科森科技股份有限公司出售全资子公司股权的监管工作函》（上证公函 [2025]4004 号，以下简称为"《监管工作函》"）有关法律问题，出具本法律意见 书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用原则， ...

昆山科森科技股份有限公司独立董事 关于出售全资子公司股权监管工作函相关事项的独立意见 昆山科森科技股份有限公司（以下简称"公司"或"科森科技"）于近日收到 上海证券交易所《关于昆山科森科技股份有限公司出售全资子公司股权的监管工 作函》（上证公函[2025]4004 号）（以下简称"《工作函》"）。作为公司独立董事， 我们根据中国证监会《上市公司独立董事管理办法》《上海证券交易所股票上市 规则》等法律法规及《公司章程》的相关规定，本着勤勉尽责的原则，与管理层 认真讨论了监管工作函的内容，基于独立判断的立场，就《工作函》有关事项发 表如下独立意见： 问题一、公告显示，科森医疗主营微创手术器械产品的加工与出口业务， 2024 年、2025 年前三季度（以下简称一年一期）分别实现营业收入 3.66 亿元、 3.54 亿元，实现净利润 4,112.18 万元、4,724.14 万元，持续盈利且同比增长，而 同期公司持续亏损。本次交易目的主要为优化整体资产配置、剥离非核心业务、 改善公司业绩等。本次交易对方为 FSP Holdings Pte. Ltd（以下简称 FSP）的新 设全资子公司江苏耀岭科医疗科技有限公司（以下 ...

中审亚太会计师事务所（特殊普通合伙） China Audit Asia Pacific Certified Public Accountants LLP 中审亚太会计师事务所（特殊普通合伙） 《关于昆山科森科技股份有限公司出售全资子公司股权的监管工作 函》中有关事项的专项说明 中审亚太审字（2025）011254号 上海证券交易所： 由昆山科森科技股份有限公司（以下简称"公司"或"科森科技"）收到上海证券交易所《关 于昆山科森科技股份有限公司出售全资子公司股权的监管工作函》（上证公函[2025]4004 号）（以 下简称"《工作函》"）已收悉。根据工作函的相关要求,对工作函涉及与会计师相关的事项进行了 核查或核实,现回复如下: 问题二：公告显示，本次交易采用收益法、市场法进行评估，最终选取收益法评估结果，截至 评估基准日 2025 年 9 月 30 日，科森医疗的股东全部权益价值为 9.13 亿元，评估增值 6.15 亿元， 增值率 206.45%。具体地，以科森医疗剔除内部交易后模拟独立运营所产生的收入与利润为基础， 即剔除公司历史上为科森医疗提供的开发技术服务、业务扩展支持及中后台服务的成本，同时考虑 科 ...

证券代码：603626 证券简称：科森科技 公告编号：2025-058 昆山科森科技股份有限公司 关于召开出售全资子公司股权说明会的公告 本公司董事会、全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2025 年 12 月 19 日（星期五）15:00-16:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （网 址 ： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 为便于广大投资者更全面深入地了解公司的经营决策，公司计划于 2025 年 12 月 19 日（星期五）15:00-16:00 召开关于出售全资子公司股权的说明会，就投 资者关心的问题进行交流。 一、 说明会类型 昆山科森科技股份有限公司（以下简称"公司"）于 2025 年 12 月 8 日召开 第四届董事会第二十四次会议，审议通过了《关于出售全资子公司股权的议案》， 详见公司于 2025 年 12 月 9 日在《中国证券报》、《上海证券报》、《证券时报》及 上海 ...